Actuate Therapeutics (ACTU) Stock News

Actuate Therapeutics (NASDAQ: ACTU) announced its inclusion in the Russell 3000® and Russell 2000® Indexes, effective June 27, 2025, following its IPO last year. The Russell 3000® Index tracks the top 3,000 U.S. public companies, while the Russell 2000® focuses on small-cap stocks. The inclusion comes after positive Phase 2 trial results for their lead candidate elraglusib in metastatic pancreatic ductal adenocarcinoma (mPDAC), which showed significant improvement in median overall survival (10.1 months vs 7.2 months, p=0.01) with a 37% reduction in death risk. Approximately $10.6 trillion in assets are benchmarked against Russell U.S. Indexes as of May 2025, making this inclusion a significant milestone for Actuate's visibility in the investment community.

Actuate Therapeutics (NASDAQ: ACTU) announced positive Phase 2 trial results for elraglusib combined with gemcitabine/nab-paclitaxel (GnP) in treating metastatic pancreatic cancer. The trial met its primary endpoint with significant survival improvements: median overall survival increased to 10.1 months vs 7.2 months (p=0.01), and 12-month survival rate doubled to 44.1% vs 22.3%. The drug showed continued benefits at 18 and 24 months, with survival rates of 19.7% vs 4.4% and 13.8% vs 0% respectively. The treatment demonstrated a favorable safety profile, with mostly Grade 1-2 adverse events, primarily including reversible visual impairments. The study also showed improved response rates (29.0% vs 21.8%) and progression-free survival (5.6 vs 5.1 months). Key opinion leaders emphasized the significance of these results, highlighting elraglusib's potential to reshape metastatic pancreatic cancer treatment through its unique immune-modulating mechanism.

Actuate Therapeutics (NASDAQ: ACTU) announced positive Phase 2 trial results for elraglusib in treating metastatic pancreatic cancer, presented at ASCO 2025. The trial met its primary endpoint, showing significant improvement in median overall survival (10.1 months vs 7.2 months) when elraglusib was combined with standard chemotherapy (GnP). The treatment reduced death risk by 37% and doubled the 1-year survival rate to 44.1% compared to 22.3% with GnP alone. The drug demonstrated a manageable safety profile with mostly Grade 1-2 adverse events. Biomarker analysis confirmed the drug's immune-modulating mechanism. Based on these promising results, Actuate plans to engage with FDA and EMA in H2 2025 to discuss registration pathway.

Actuate Therapeutics (NASDAQ: ACTU) has announced positive Phase 2 trial results for elraglusib in treating metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial, involving 286 patients, demonstrated that the combination of elraglusib with gemcitabine/nab-paclitaxel (GnP) achieved statistically significant improvements in median overall survival and 1-year survival rates compared to GnP alone. The study also showed increased Objective Response Rates and Disease Control Rates. The detailed findings will be presented at the 2025 ASCO Annual Meeting on May 31, 2025, by Dr. Devalingam Mahalingam of Northwestern University. The company will host a KOL event featuring distinguished experts to discuss the results. Elraglusib, administered at 9.3 mg/kg by IV infusion, works by inhibiting GSK-3β to potentially enhance chemotherapy activity and activate anti-tumor immunity.

Actuate Therapeutics (NASDAQ: ACTU) announced a key opinion leader (KOL) event to discuss topline Phase 2 clinical data for elraglusib in metastatic pancreatic ductal adenocarcinoma (mPDAC). The event, scheduled for May 31, 2025, will feature a fireside discussion with distinguished experts from leading medical institutions. The Phase 2 study (Actuate-1801 Part 3B) involved 286 mPDAC patients randomized 2:1 to receive either elraglusib with gemcitabine/nab-paclitaxel (GnP) or GnP alone. The trial's primary endpoint is 1-year survival rate, with median overall survival as the primary parameter. Elraglusib, administered at 9.3 mg/kg by IV infusion, works by inhibiting GSK-3β to potentially enhance chemotherapy activity and activate anti-tumor immunity.

Actuate Therapeutics (NASDAQ: ACTU) announced significant topline results from its Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial met its primary endpoints, demonstrating statistically significant improvement in overall survival and one-year survival rates compared to GnP control arm.

The elraglusib/GnP combination showed a substantial improvement in median overall survival since December 2024's analysis, with a favorable risk-benefit profile. The complete topline dataset will be presented at the ASCO Annual Meeting on May 31, 2025. The company plans to engage with US and EU regulators in H2 2025 to advance elraglusib towards NDA and registration.

This development represents the first major advance in first-line treatment survival for metastatic pancreatic cancer in over a decade.

Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company, has announced its participation in the upcoming Citizens Life Sciences Conference 2025. The event will take place on May 7-8 in New York, NY.

Daniel Schmitt, President & CEO of Actuate, will deliver a presentation on Thursday, May 8, 2025, at 12:30 PM ET. The company, which specializes in developing treatments for difficult-to-treat cancers through GSK-3β inhibition, will make the presentation webcast available in their Investor section.

The management team will also conduct one-on-one meetings with investors during the conference. Interested investors should coordinate with their Citizens JMP representatives to schedule meetings.

Actuate Therapeutics (NASDAQ: ACTU) has announced that topline data from its Phase 2 study of elraglusib will be presented at the 2025 ASCO Annual Meeting. The presentation will focus on results from the Actuate-1801 Part 3B trial, which evaluated elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).

The oral presentation, scheduled for May 31, 2025, at 3:00 PM CDT, will be part of the Gastrointestinal Cancer session at the conference taking place in Chicago from May 30 to June 3. The study represents a significant milestone in the company's development of therapies targeting GSK-3β inhibition for difficult-to-treat cancers.

Actuate Therapeutics (NASDAQ: ACTU) will present significant data on their cancer drug elraglusib at the AACR Annual Meeting 2025 in Chicago from April 25-30. The presentation focuses on elraglusib's effectiveness in treating advanced salivary gland carcinoma when combined with chemotherapy and immunotherapy.

The first poster presentation (CT212) on April 29 will showcase elraglusib's performance as a GSK-3β inhibitor in advanced salivary cancers. Dr. Glenn Hanna from Dana Farber Cancer Institute reported encouraging response rates in non-Adenoid Cystic Carcinoma patients with nuclear GSK-3β overexpression.

Additionally, researchers from Brown University's Legorreta Cancer Center will present findings on April 28 demonstrating elraglusib's synergistic effects when combined with Jazz Pharmaceuticals' investigational compounds ONC206 and ONC212 for solid cancer treatment.